111 Capital Takes Position in Vaxcyte, Inc. $PCVX

Key Points

• 111 Capital has acquired a new position in Vaxcyte, Inc. by purchasing 10,991 shares valued at approximately $357,000.
• Vaxcyte recently reported quarterly earnings, with an earnings per share of ($1.22), missing analysts' expectations.
• The stock has a current market capitalization of $5.54 billion and an average price target from analysts of $106.25.

111 Capital bought a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 10,991 shares of the company's stock, valued at approximately $357,000.

Several other large investors have also recently bought and sold shares of PCVX. AlphaQuest LLC bought a new position in shares of Vaxcyte in the first quarter worth $33,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in Vaxcyte in the 1st quarter worth about $35,000. Parallel Advisors LLC raised its holdings in shares of Vaxcyte by 203.6% in the 1st quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock valued at $61,000 after acquiring an additional 1,071 shares in the last quarter. IFP Advisors Inc raised its holdings in shares of Vaxcyte by 376.4% in the 1st quarter. IFP Advisors Inc now owns 1,653 shares of the company's stock valued at $62,000 after acquiring an additional 1,306 shares in the last quarter. Finally, Advisors Asset Management Inc. boosted its position in shares of Vaxcyte by 81.6% during the 1st quarter. Advisors Asset Management Inc. now owns 1,929 shares of the company's stock valued at $73,000 after acquiring an additional 867 shares during the last quarter. 96.78% of the stock is owned by institutional investors.

Vaxcyte Price Performance

PCVX opened at $42.66 on Monday. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $118.62. The business has a 50 day simple moving average of $32.73 and a two-hundred day simple moving average of $34.70. The firm has a market capitalization of $5.54 billion, a price-to-earnings ratio of -10.38 and a beta of 1.12.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($1.22) earnings per share for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same period in the previous year, the company posted ($1.10) earnings per share. As a group, sell-side analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Analyst Ratings Changes

PCVX has been the topic of several research analyst reports. Cowen restated a "buy" rating on shares of Vaxcyte in a research report on Thursday, August 7th. The Goldman Sachs Group began coverage on shares of Vaxcyte in a research report on Friday, September 12th. They set a "neutral" rating and a $38.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Vaxcyte in a report on Saturday, September 27th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $106.25.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.